Cancer Clinical Trial
Official title:
VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer: A Randomized, Double-Blinded, Placebo Controlled Trial
Verified date | October 2023 |
Source | University of Calgary |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the prevention of immune checkpoint inhibitors (ICIs) related diarrhea/colitis using vedolizumab in participants with unresectable stage III or metastatic stage IV cancer, starting standard of care (SOC) immunotherapy
Status | Not yet recruiting |
Enrollment | 298 |
Est. completion date | December 1, 2026 |
Est. primary completion date | November 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Signed informed consent prior to initiation of any study specific activities or procedures - Diagnosed with unresectable advanced stage III or metastatic stage IV malignancy - Planned for initiation of SOC immunotherapy and development of prognostic biomarker evidence that predisposes to ICI diarrhea/colitis risk - Ability to and willingness to adhere to the randomized treatment interventions (vedolizumab or placebo), administered intravenously Exclusion Criteria: - Condition(s) for which vedolizumab is contraindicated (e.g., hypersensitivity reaction, known allergic reaction to vedolizumab or its components) - Current or prior use of vedolizumab or prior immunotherapy exposure for cancer - Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis), indeterminate colitis, or microscopic colitis - Presence of ileostomy, colostomy, or short bowel syndrome - Presence of known luminal gastrointestinal metastases at baseline - Presence of significant pre-existing autoimmune disease (at investigator's discretion) - Presence of severe infection(s) or opportunistic infection(s) - Active enteric infection with viral, bacterial, or parasitic pathogens - Presence of untreated latent or active tuberculosis, or untreated chronic hepatitis B virus - Baseline ECOG status grade =3 - Pregnancy or lactation - Treatment with another investigational product within 8 weeks of randomization - Requirement for baseline anti-diarrheal treatment(s) (including but not limited to loperamide, diphenoxylate-atropine, octreotide, tincture of opium), anticholinergic drug(s), or opioid-based analgesic(s) used specifically for diarrhea control within 14 days of randomization - Any condition or diagnosis, that could in the opinion of the Qualified Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Calgary |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hazard Ratio of Patients achieving ICI-related diarrhea and colitis-free survival a 6-months | ICI-related diarrhea and colitis will be assessed using Common Terminology Criteria for Adverse Events (CTCAE), and a grade =2 will be considered an event. | Start of immunotherapy therapy and for 6 months | |
Secondary | Proportion of patients with histologically confirmed colitis-free survival at 6 months | Colitis-free survival will be defined as CTCAE grade =2 based on a biopsy taken at time of patient meeting the primary endpoint or at 6 months. | 6 months | |
Secondary | Proportion of patients with severe diarrhea or colitis at 6 months | Severe diarrhea or colitis will be defined as CTCAE grade =3 | 6 months | |
Secondary | Hazard Ratio of patients with diarrhea or colitis after 6 months | Diarrhea or colitis will be defined as CTCAE grade =2 | 6-12 months | |
Secondary | Total average dose of checkpoint inhibitor therapy received within 6 and 12 months | The total average dose of ICI therapy will be used | 0 to 6 months; and 0 to 12 months | |
Secondary | Proportion of participants who require temporary ICI discontinuation due to immune-related adverse events (irAEs) | Temporary discontinuation of ICI therapy will be defined as any delay of 1-week or more resulting from an immune-related adverse event (irAE), as identified and graded using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 0 to 12 months | |
Secondary | Proportion of participants who require permanent ICI discontinuation due to irAEs | Permanent discontinuation of ICI therapy will be defined as stopping ICI therapy, and not restarting within the 1-year time window of the trial resulting from an immune-related adverse event (irAE), as identified and graded using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 0 to 12 months | |
Secondary | Proportion of patients requiring rescue corticosteroids for ICI related diarrhea/colitis | Any patient who receives rescue corticosteroids within the first 6 months or within the first 12 months will be considered an event. | at 6-months and 12-months | |
Secondary | Total average prednisone equivalent dose of rescue corticosteroids required | The prednisone equivalent dose will be calculated using the following conversions:
Cortisone 5mg = Prednisone 1mg Hydrocortisone 4mg = Prednisone 1mg Prednisolone 1mg = Prednisone 1mg Methylprednisolone 0.8mg = Prednisone 1mg Dexamethasone 0.15mg = Prednisone 1mg |
at 6-months and 12-months | |
Secondary | Proportion of participants requiring all-cause hospitalization by Day +180 and Day +365 | Chart review will be used to identify hospitalizations. | at day 180 and 365 | |
Secondary | Proportion of participants requiring ICI-related diarrhea/colitis-specific hospitalization by Day +180 and Day +365 | Chart review will be used to identify hospitalization and determine the cause of hospitalization. | at day 180; at day 365 | |
Secondary | Mean change in the EuroQol EQ-5D instrument at Day +180 and Day +365 compared to baseline | The EuroQol EQ-5D is a validated questionnaire for patients with inflammatory bowel disease. | baseline to day 180; baseline to day 365 | |
Secondary | Overall survival (measured as death) at +180 and Day +365 compared to baseline | All-cause mortality will be used to compare the survival rate of the therapy and placebo arms. The rates will be calculated for 6 months (defined at day 180) and 1-year (day 365). | Day +180 and Day +365 | |
Secondary | Progression-free survival at 6- and 12-months, defined using the Response Evaluation Criteria in Solid Tumors (RECIST), v1.176 | Progression-free survival will be defined using the Response Evaluation Criteria in Solid Tumors (RECIST), v1.176 | At Day +180 and Day +365 | |
Secondary | Proportion of participants experiencing any adverse events (AEs) | Adverse events will be defined as described in good clinical practice. | At Day +180 and Day +365 | |
Secondary | Proportion of participants experiencing serious AEs | Serious adverse events will be defined as described in good clinical practice. | At Day +180 and Day +365 | |
Secondary | Proportion of participants experiencing other irAEs | Adverse events will be defined as described in good clinical practice. Those that are immune related will be used for this outcome. | At Day +180 and Day +365 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|